We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
Shares of Bristol-Myers Squibb Co. (BMY) and Celgene Corp. (CELG) are both in the red in Monday's market, following news their planned merger would be delayed due to antitrust concerns.
At 2:51 p.m. ET, Bristol-Myers Squibb shares had lost 7.4%, to trade at $45.69. Volume was heavier than usual, with over 29.1 million shares trading, above the 65-day average volume of some 14.6 million. Celgene shares had lost 5.34%, trading at $93.63. That stock's volume was also higher than usual with over 7.2 million shares trading, above its 65-day average volume of some 6.6 million.
The $74 billion merger faces delays as the companies work to sell Celgene's anti-inflammatory drug, Otzela, in an effort to address concerns raised by antitrust regulators.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 24, 2019 15:15 ET (19:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
